What Is Imcivree?

1. How does Imcivree work, and why is it not a GLP-1 drug?

Body weight is regulated partly by a chain of signals in the hypothalamus. Fat tissue releases leptin; leptin acts on its receptor (LEPR) on neurons that make POMC; POMC is cut by the enzyme PCSK1 into melanocortin hormones; and those hormones switch on the MC4 receptor, which reduces hunger and raises energy use. A break anywhere along that chain leaves the MC4 receptor under-stimulated, and the result is intense hunger, called hyperphagia, and early, severe obesity.

The Imcivree label describes setmelanotide as an MC4 receptor agonist with about 20-fold less activity at the MC3 and MC1 receptors. By acting directly on MC4, it may restore the pathway’s signal downstream of the break, reducing food intake and increasing energy expenditure. The label says the drug also activates MC1 receptors on pigment cells, which causes melanin to build up and the skin to darken regardless of sun exposure.

GLP-1 drugs such as semaglutide act on a different system: receptors for a gut hormone released after meals, which slow the stomach and signal fullness to the brain. Both classes reduce appetite, but by different routes. That difference explains Imcivree’s narrow label. Where the leptin-melanocortin pathway is intact, as in most obesity, the label says setmelanotide “would not be expected to be effective.” In a short study of 12 people with general obesity, the label notes it raised resting energy expenditure, but safety and effectiveness have not been established in that group.

The same receptor family links Imcivree to bremelanotide, sold as Vyleesi, which acts mainly on MC4 and MC1 for a sexual desire indication. That overlap explains why both drugs share skin darkening and sexual side effects.

2. Who is Imcivree approved for?

The US label, as of November 2026, covers three groups:

Bardet-Biedl syndrome is a rare inherited ciliopathy, a disorder of the tiny antenna-like structures on cells; the phase 3 trial paper describes impaired cilia signaling in the MC4R pathway as a likely contributor to its hunger and early, severe obesity. POMC, PCSK1 and LEPR deficiencies are rare single-gene disorders in the leptin pathway. The label notes that no FDA-approved test for these gene variants exists.

The label is just as explicit about who is excluded: people whose variants are classified as benign or likely benign, people with obesity from other genetic syndromes, and people with general polygenic obesity. Imcivree is not an option for someone with ordinary obesity who has not responded to a GLP-1 drug, unless one of these diagnoses applies.

How the label grew

3. What did TRANSCEND show in hypothalamic obesity?

Acquired hypothalamic obesity follows damage to the hypothalamus, defined in TRANSCEND as a history of a hypothalamic tumor, lesion or injury. Obesity after craniopharyngioma, a tumor in that region, is one well-studied form; the CRANIOEXE trial in section 7 enrolled only such patients.

TRANSCEND, published in the New England Journal of Medicine in July 2026, randomized people aged 4 to 66 with a history of hypothalamic tumor, lesion or injury and obesity 2:1 to setmelanotide or placebo for 52 weeks after a dose-escalation period. The label’s analysis, which included 142 patients and was stratified by age group and by Japanese versus non-Japanese subpopulation, reported:

The NEJM paper’s main cohort of 120 participants (81 on setmelanotide, 39 on placebo) reported BMI changes of -16.5% versus +3.3% and hunger score changes of -2.73 versus -1.45. Serious adverse events occurred in 28% on setmelanotide and 8% on placebo. The label also notes reductions in waist circumference and numeric improvements in blood pressure, lipids and glucose measures.

Two cautions. The 10% and 15% thresholds were not controlled for multiple testing, and BMI after week 52 was missing for 13% of the setmelanotide group. And the trial lasted a year, so durability beyond that comes from extension data, not this trial.

4. What did the genetic obesity trials show?

These are small trials, because the conditions are rare.

The withdrawal phase of the POMC and LEPR trials is the clearest evidence that the drug itself causes the effect. Responders who were switched to placebo for 4 weeks gained an average of 5.5 kg (POMC) and 5.0 kg (LEPR), their hunger scores worsened, and both improved again when Imcivree was restarted. The same feature means the benefit depends on continued daily treatment, much as weight returns after stopping GLP-1 drugs (weight regain after stopping).

The BBS trial also enrolled people with Alström syndrome, another ciliopathy, but results in that group were inconclusive, and Alström syndrome is not on the label.

5. How is Imcivree dosed?

Imcivree comes in a multi-dose vial and is injected under the skin once a day. The label starts low and increases every two weeks if tolerated, watching for stomach side effects:

The label has separate, lower schedules for severe kidney impairment, does not recommend Imcivree in end-stage kidney disease, and does not recommend it in hypothalamic obesity with severe kidney impairment. Unopened vials are refrigerated; once out of the fridge a vial can be kept at up to 77°F (25°C) for up to 30 days, and an opened vial is discarded after 30 days. The half-life of about 11 hours is why it is dosed daily.

These are the label’s doses, listed for reference. The dose titration explainer covers why most appetite drugs start low.

6. What are Imcivree’s side effects?

The hypothalamic obesity trial is the only large placebo-controlled dataset, so it gives the cleanest rates:

In the open-label genetic trials, which had no placebo group, rates were higher for some effects: in POMC, PCSK1 or LEPR deficiency (27 patients), injection-site reactions occurred in 96%, skin darkening in 78%, nausea in 56%, depression in 26% and suicidal ideation in 11%. In BBS (43 patients), skin darkening occurred in 63%, injection-site reactions in 51% and spontaneous erections in 25% of male patients.

Label warnings

• Sexual effects. Spontaneous or more frequent erections in males and sexual adverse reactions in females. An erection lasting more than 4 hours needs emergency care.
• Depression and suicidal thoughts. Patients are monitored for new or worsening mood symptoms; stopping is considered if they occur.
• Serious allergic reactions, including anaphylaxis, reported after approval.
• Skin and moles. Generalized or focal skin darkening occurred in most patients and, per the label, reverses after stopping. New moles and darkening of existing ones also occur, so a full-body skin exam is recommended before starting and periodically after.
• Adrenal crisis in hypothalamic obesity. In TRANSCEND, serious acute adrenal insufficiency occurred in 5% on Imcivree and none on placebo, in patients with existing secondary adrenal insufficiency.
• Sodium swings in hypothalamic obesity with diabetes insipidus. Low sodium in 6% versus 2%, high sodium in 5% versus 4%; sodium is monitored when fluid intake changes.

The last two warnings were added with the 2026 indication. They apply to TRANSCEND patients who already had secondary adrenal insufficiency or central diabetes insipidus, conditions that can accompany hypothalamic damage, and they mean the doses of those patients’ other treatments may need adjusting. The label recommends discontinuing Imcivree in pregnancy unless benefits outweigh risks and does not recommend it while breastfeeding.

7. How does Imcivree compare with GLP-1 drugs in hypothalamic obesity?

GLP-1 drugs were studied and used off-label in hypothalamic obesity before Imcivree’s 2026 approval, so the comparison matters. No head-to-head trial exists, and the evidence on each side is different in kind.

The two randomized exenatide trials missed their weight endpoints, although exenatide also lost to semaglutide on weight in head-to-head diabetes trials (see Bydureon), so its results may not represent newer drugs. The semaglutide data are encouraging but uncontrolled, so they cannot be compared directly with TRANSCEND’s placebo-controlled result. The honest summary is that setmelanotide has the stronger controlled evidence in this condition, and semaglutide has not been tested against placebo in it in the studies found for this page.

On combining the two: the label gives no data, no combination trial turned up, and Rhythm’s 2026 filings say nothing about GLP-1 drugs. The side-effect overlap is obvious, since both cause nausea and vomiting, and so is the appeal, since the drugs work on different parts of the appetite system. That remains a question for specialists and future trials.

8. Where is Imcivree approved outside the US, and what is next?

• European Union. First authorized on July 16, 2021, and an orphan medicine. The EMA’s current indication covers acquired hypothalamic obesity from age 4 and genetically confirmed BBS or POMC (including PCSK1) or biallelic LEPR deficiency from age 2, following a CHMP opinion published in March 2026. Rhythm’s November 3, 2026 release says country launches for hypothalamic obesity are expected to begin with Germany in 2027.
• Japan. The health ministry approved Imcivree for acquired hypothalamic obesity on August 24, 2026, and Rhythm announced the commercial launch on October 13, 2026.
• US uptake. Rhythm reported more than 700 patient start forms for hypothalamic obesity from more than 500 prescribers by September 30, 2026, and global Imcivree revenue of $92.1 million in the third quarter of 2026, up from $71.3 million in the second quarter.

Rhythm’s pipeline, per the same filings, includes bivamelagon, an MC4R agonist it plans to take into a pivotal Phase 3 trial in acquired hypothalamic obesity by year-end 2026, and RM-718, a weekly injectable MC4R agonist in Phase 1/2 testing, including in Prader-Willi syndrome. A setmelanotide substudy in congenital hypothalamic obesity is expected to finish enrolling in 2027. None of these are approved uses.

9. What is worth tracking on Imcivree?

The label points to the measures that matter: weight or BMI (and BMI percentile in children), a hunger rating, injection site, nausea and vomiting during each titration step, mood changes, and any new or darkening moles between skin exams. For people with hypothalamic obesity, signs of adrenal crisis and changes in thirst, fluid intake and sodium results are part of the picture too. A daily GLP-1 and peptide log works the same way for Imcivree as for a weekly drug, with one difference: a missed daily dose shows up quickly as hunger, so recording the dose and the next day’s hunger score together makes patterns easier to spot.

10. Imcivree FAQ

• Who is Imcivree approved for?

  In the US, people with acquired hypothalamic obesity aged 4 and older, and people aged 2 and older with Bardet-Biedl syndrome or with POMC, PCSK1 or LEPR deficiency confirmed by genetic testing showing pathogenic, likely pathogenic or uncertain-significance variants. The label says it is not indicated, and would not be expected to work, in general (polygenic) obesity, in other genetic syndromes, or when the POMC, PCSK1 or LEPR variants are benign or likely benign.

• What is acquired hypothalamic obesity?

  Weight gain after damage to the hypothalamus, the brain region that regulates hunger and energy use. In the TRANSCEND trial it was defined as obesity plus a history of a hypothalamic tumor, lesion or injury. Obesity after craniopharyngioma, a tumor in that region, is one well-studied form.

• Is Imcivree a GLP-1 drug?

  No. GLP-1 drugs act on receptors for a gut hormone that rises after meals. Imcivree acts further down the brain's own appetite pathway, on the MC4 receptor that leptin normally switches on through POMC. That is why it can work when the upstream pathway is broken by a gene variant or hypothalamic injury.

• How much weight do people lose on Imcivree?

  It depends on the condition. In acquired hypothalamic obesity, BMI fell 15.8% on Imcivree and rose 2.6% on placebo over 52 weeks in the label's analysis. In Bardet-Biedl syndrome, mean BMI fell 7.9% after 52 weeks of open-label treatment. In POMC or PCSK1 deficiency, weight fell a mean 23.1% in a year, and in LEPR deficiency 9.7%.

• What are the side effects of Imcivree?

  In the hypothalamic obesity trial: skin darkening 58% versus 10% on placebo, nausea 55% versus 25%, vomiting 38% versus 19%, headache 37% versus 31%, and new or darker moles 15% versus 6%. Across indications the label also lists injection-site reactions, spontaneous erections, depression and suicidal thoughts, and serious allergic reactions. The skin darkening reverses after stopping, according to the label.

• How is Imcivree taken?

  As a once-daily injection under the skin from a multi-dose vial. The label starts low and raises the dose every two weeks as tolerated: in hypothalamic obesity it starts at 0.5 mg; in BBS or POMC, PCSK1 or LEPR deficiency, at 2 mg from age 12, 1 mg at ages 6 to 11, and 0.5 mg at ages 2 to 5. The usual maintenance dose from age 6 is 3 mg daily; younger children are dosed by weight.

• Can Imcivree be used with a GLP-1 drug?

  The label gives no data on combining them, and no trial of the combination was found for this page. GLP-1 drugs have their own mixed record in hypothalamic obesity: placebo-controlled exenatide trials missed their weight endpoints, while uncontrolled semaglutide reports were more encouraging. Any combination is a specialist decision.

• What happens if Imcivree is stopped?

  The weight comes back. In the POMC and LEPR trials, people who had responded and were switched to placebo for 4 weeks regained an average of 5.5 kg and 5.0 kg, and hunger scores worsened; both improved again when the drug was restarted.

11. Sources